Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy

Advanced Drug Delivery Reviews

Volumn 61, Issue 5, 2009, Pages 381-387

  Marsh, Sharon ^a   Liu, Geoffrey ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Breast cancer; Chemotherapy; Pharmacogenomics; Pharmacokinetics; Polymorphism

Indexed keywords

ALKYLATING AGENTS; ANTHRACYCLINES; BREAST CANCER; PHARMACOGENOMICS; PLATINUM DRUGS; TAXANES;

PHARMACOKINETICS; PLATINUM; POLYMORPHISM;

CHEMOTHERAPY;

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; THIOTEPA; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; DRUG CLEARANCE; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 65049085938     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.10.003     Document Type: Review

References (73)

1. Turner N.C., and Jones A.L. Management of breast cancer-part I. BMJ 337 (2008) a421
2. Choueiri T.K., Alemany C.A., Abou-Jawde R.M., and Budd G.T. Role of aromatase inhibitors in the treatment of breast cancer. Clin. Ther. 26 (2004) 1199-1214
3. Lin N.U., and Winer E.P. Advances in adjuvant endocrine therapy for postmenopausal women. J. Clin. Oncol. 26 (2008) 798-805
4. Nabholtz J.M. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther. Clin. Risk. Manag. 4 (2008) 189-204
5. Plosker G.L., and Keam S.J. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66 (2006) 449-475
6. Leveque D., Gigou L., and Bergerat J.P. Clinical pharmacology of trastuzumab. Curr. Clin. Pharmacol. 3 (2008) 51-55
7. Yan L., Hsu K., and Beckman R.A. Antibody-based therapy for solid tumors. Cancer J. 14 (2008) 178-183
8. Gligorov J., and Lotz J.P. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 Suppl 2 (2004) 3-8
9. Somlo G., Doroshow J.H., Synold T., Longmate J., Reardon D., Chow W., Forman S.J., Leong L.A., Margolin K.A., Morgan Jr. R.J., Raschko J.W., Shibata S.I., Tetef M.L., Yen Y., Kogut N., Schriber J., and Alvarnas J. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br. J. Cancer 84 (2001) 1591-1598
10. ten Tije A.J., Verweij J., Loos W.J., and Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42 (2003) 665-685
11. Baker S.D., Sparreboom A., and Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin. Pharmacokinet. 45 (2006) 235-252
12. Komoroski B.J., Parise R.A., Egorin M.J., Strom S.C., and Venkataramanan R. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin. Cancer Res. 11 (2005) 6972-6979
13. Urien S., Barre J., Morin C., Paccaly A., Montay G., and Tillement J.P. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest. New Drugs 14 (1996) 147-151
14. Loos W.J., Baker S.D., Verweij J., Boonstra J.G., and Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin. Pharmacol. Ther. 74 (2003) 364-371
15. Kumar G.N., Walle U.K., Bhalla K.N., and Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res. Commun. Chem. Pathol. Pharmacol. 80 (1993) 337-344
16. Bruno R., Olivares R., Berille J., Chaikin P., Vivier N., Hammershaimb L., Rhodes G.R., and Rigas J.R. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin. Cancer Res. 9 (2003) 1077-1082
17. Hansen J.E., Larsen V.A., and Bog-Hansen T.C. The microheterogeneity of alpha 1-acid glycoprotein in inflammatory lung disease, cancer of the lung and normal health. Clin. Chim. Acta 138 (1984) 41-47
18. Nakamura T., Board P.G., Matsushita K., Tanaka H., Matsuyama T., and Matsuda T. Alpha 1-acid glycoprotein expression in human leukocytes: possible correlation between alpha 1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritis. Inflammation 17 (1993) 33-45
19. Iscan M., Klaavuniemi T., Coban T., Kapucuoglu N., Pelkonen O., and Raunio H. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res. Treat. 70 (2001) 47-54
20. Steed H., and Sawyer M.B. Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 8 (2007) 803-815
21. Marsh S. Taxane pharmacogenetics. Personalized Med. 3 (2006) 33-43
22. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., and Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25 (2007) 4528-4535
23. Marsh S., Somlo G., Li X., Frankel P., King C.R., Shannon W.D., McLeod H.L., and Synold T.W. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7 (2007) 362-365
24. McFadyen M.C., Cruickshank M.E., Miller I.D., McLeod H.L., Melvin W.T., Haites N.E., Parkin D., and Murray G.I. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer 85 (2001) 242-246
25. McKay J.A., Melvin W.T., Ah-See A.K., Ewen S.W., Greenlee W.F., Marcus C.B., Burke M.D., and Murray G.I. Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett. 374 (1995) 270-272
26. Murray G.I., Taylor M.C., McFadyen M.C., McKay J.A., Greenlee W.F., Burke M.D., and Melvin W.T. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57 (1997) 3026-3031
27. Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., Mariani G., Rodriguez J., Carcangiu M., Watson D., Valagussa P., Rouzier R., Symmans W.F., Ross J.S., Hortobagyi G.N., Pusztai L., and Shak S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23 (2005) 7265-7277
28. Gehrmann M., Schmidt M., Brase J.C., Roos P., and Hengstler J.G. Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?. Pharmacogenomics 9 (2008) 969-974
29. Chang J.C., Makris A., Gutierrez M.C., Hilsenbeck S.G., Hackett J.R., Jeong J., Liu M.L., Baker J., Clark-Langone K., Baehner F.L., Sexton K., Mohsin S., Gray T., Alvarez L., Chamness G.C., Osborne C.K., and Shak S. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res. Treat. (2007)
30. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., Lopez-Vivanco G., Camps C., Botia M., Nunez L., Sanchez-Ronco M., Sanchez J.J., Lopez-Brea M., Barneto I., Paredes A., Medina B., Artal A., and Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15 (2004) 1194-1203
31. Mano M. Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy. Cancer Treat. Rev. 32 (2006) 106-118
32. Deporte-Fety R., Simon N., Fumoleau P., Campone M., Kerbrat P., Bonneterre J., Fargeot P., and Urien S. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 53 (2004) 233-238
33. Wong M., Balleine R.L., Blair E.Y., McLachlan A.J., Ackland S.P., Garg M.B., Evans S., Farlow D., Collins M., Rivory L.P., Hoskins J.M., Mann G.J., Clarke C.L., and Gurney H. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J. Clin. Oncol. 24 (2006) 2448-2455
34. Pan J.H., Han J.X., Wu J.M., Sheng L.J., Huang H.N., and Yu Q.Z. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75 (2008) 380-385
35. Pan J.H., Han J.X., Wu J.M., Sheng L.J., and Huang H.N. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer. Acta Oncol. 46 (2007) 361-366
36. Schott A.F., Rae J.M., Griffith K.A., Hayes D.F., Sterns V., and Baker L.H. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother. Pharmacol. 58 (2006) 129-135
37. Hassan M., Svensson U.S., Ljungman P., Bjorkstrand B., Olsson H., Bielenstein M., Abdel-Rehim M., Nilsson C., Johansson M., and Karlsson M.O. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br. J. Clin. Pharmacol. 48 (1999) 669-677
38. Powis G., Reece P., Ahmann D.L., and Ingle J.N. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother. Pharmacol. 20 (1987) 219-222
39. Gheuens E., Slee P.H., and de Bruijn E.A. Bioavailability of cyclophosphamide in the CMF regimen. Onkologie 13 (1990) 203-206
40. Petros W.P., Hopkins P.J., Spruill S., Broadwater G., Vredenburgh J.J., Colvin O.M., Peters W.P., Jones R.B., Hall J., and Marks J.R. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J. Clin. Oncol. 23 (2005) 6117-6125
41. Nakajima M., Komagata S., Fujiki Y., Kanada Y., Ebi H., Itoh K., Mukai H., Yokoi T., and Minami H. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet. Genomics 17 (2007) 431-445
42. Ekhart C., Doodeman V.D., Rodenhuis S., Smits P.H., Beijnen J.H., and Huitema A.D. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet. Genomics 18 (2008) 515-523
43. Sugiyama E., Kaniwa N., Kim S.R., Kikura-Hanajiri R., Hasegawa R., Maekawa K., Saito Y., Ozawa S., Sawada J., Kamatani N., Furuse J., Ishii H., Yoshida T., Ueno H., Okusaka T., and Saijo N. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25 (2007) 32-42
44. Marsh S. Pharmacogenetics of colorectal cancer. Expert. Opin. Pharmacother. 6 (2005) 2607-2616
45. Shrubsole M.J., Shu X.O., Ruan Z.X., Cai Q., Cai H., Niu Q., Gao Y.T., and Zheng W. MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study. Breast Cancer Res. Treat. 91 (2005) 73-79
46. Pare L., Altes A., Ramon y Cajal T., Del Rio E., Alonso C., Sedano L., Barnadas A., and Baiget M. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy. Anticancer Drugs 18 (2007) 821-825
47. Ribelles N., Lopez-Siles J., Sanchez A., Gonzalez E., Sanchez M.J., Carabantes F., Sanchez-Rovira P., Marquez A., Duenas R., Sevilla I., and Alba E. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr. Drug. Metab. 9 (2008) 336-343
48. Rha S.Y., Jeung H.C., Choi Y.H., Yang W.I., Yoo J.H., Kim B.S., Roh J.K., and Chung H.C. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 12 (2007) 622-630
49. Lamba J.K., Crews K., Pounds S., Schuetz E.G., Gresham J., Gandhi V., Plunkett W., Rubnitz J., and Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J. Pharmacol. Exp. Ther. 323 (2007) 935-945
50. O'Brien M.E. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 19 (2008) 1-7
51. Perez-Manga G., Lluch A., Alba E., Moreno-Nogueira J.A., Palomero M., Garcia-Conde J., Khayat D., and Rivelles N. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J. Clin. Oncol. 18 (2000) 2545-2552
52. Rushing D.A., Piscitelli S.C., Rodvold K.A., and Tewksbury D.A. The disposition of doxorubicin on repeated dosing. J. Clin. Pharmacol. 33 (1993) 698-702
53. Mross K., Maessen P., van der Vijgh W.J., Gall H., Boven E., and Pinedo H.M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J. Clin. Oncol. 6 (1988) 517-526
54. Pritchard K.I., Messersmith H., Elavathil L., Trudeau M., O'Malley F., and Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 26 (2008) 736-744
55. Fan L., Goh B.C., Wong C.I., Sukri N., Lim S.E., Tan S.H., Guo J.Y., Lim R., Yap H.L., Khoo Y.M., Iau P., Lee H.S., and Lee S.C. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet. Genomics 18 (2008) 623-631
56. Lal S., Wong Z.W., Sandanaraj E., Xiang X., Ang P.C., Lee E.J., and Chowbay B. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 99 (2008) 816-823
57. Engen R.M., Marsh S., Van Booven D.J., and McLeod H.L. Ethnic differences in pharmacogenetically relevant genes. Curr. Drug Targets 7 (2006) 1641-1648
58. Lal S., Wong Z.W., Jada S.R., Xiang X., Chen Shu X., Ang P.C., Figg W.D., Lee E.J., and Chowbay B. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8 (2007) 567-575
59. Hunz M., Jetter A., Warm M., Pantke E., Tuscher M., Hempel G., Jaehde U., Untch M., Kurbacher C., and Fuhr U. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin. Pharmacol. Ther. 81 (2007) 659-668
60. Innocenti F., Iyer L., Ramirez J., Green M.D., and Ratain M.J. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab. Dispos. 29 (2001) 686-692
61. Fagerholm R., Hofstetter B., Tommiska J., Aaltonen K., Vrtel R., Syrjakoski K., Kallioniemi A., Kilpivaara O., Mannermaa A., Kosma V.M., Uusitupa M., Eskelinen M., Kataja V., Aittomaki K., von Smitten K., Heikkila P., Lukas J., Holli K., Bartkova J., Blomqvist C., Bartek J., and Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat. Genet. 40 (2008) 844-853
62. O'Brien M.E., Talbot D.C., and Smith I.E. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J. Clin. Oncol. 11 (1993) 2112-2117
63. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., Kim Y.C., and Hwang T.S. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44 (2004) 311-316
64. Tibaldi C., Giovannetti E., Vasile E., Mey V., Laan A.C., Nannizzi S., Di Marsico R., Antonuzzo A., Orlandini C., Ricciardi S., Del Tacca M., Peters G.J., Falcone A., and Danesi R. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14 (2008) 1797-1803
65. Dolan M.E., Newbold K.G., Nagasubramanian R., Wu X., Ratain M.J., Cook Jr. E.H., and Badner J.A. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64 (2004) 4353-4356
66. Watters J.W., Kraja A., Meucci M.A., Province M.A., and McLeod H.L. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11809-11814
67. Jaremko M., Justenhoven C., Schroth W., Abraham B.K., Fritz P., Vollmert C., Illig T., Simon W., Schwab M., and Brauch H. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet. Genomics 17 (2007) 529-538
68. S. Marsh, Concordance Between Tumor and Germline DNA. Humana Press; in press. (Innocenti F, ed. Pharmacogenomics, Anticancer Drug Discovery, and Response).
69. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur. J. Cancer 40 (2004) 2667-2675
70. Mook S., Van't Veer L.J., Rutgers E.J., Piccart-Gebhart M.J., and Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 4 (2007) 147-155
71. M. Cuadros, R. Villegas, Systematic review of HER2 breast cancer testing, Appl. Immunohistochem. Mol. Morphol. (in press).
72. Ratain M.J. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin. Cancer Res. 12 (2006) 1658-1660
73. Hoskins J.M., Goldberg R.M., Qu P., Ibrahim J.G., and McLeod H.L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst. 99 (2007) 1290-1295